Author:
Urias Eduardo,Ramani Shyama V.
Publisher
Springer Science and Business Media LLC
Reference60 articles.
1. Amin, T., & Kesselheim, A. S. 2012. Secondary patenting of branded pharmaceuticals: A case study of how patents on two HIV drugs could be extended for decades. Health Affairs, 31(10): 2286–2294. https://doi.org/10.1377/hlthaff.2012.0107.
2. Babovic, S., & Wasan, K. M. 2011. Impact of the trade-related aspects of intellectual property rights (TRIPS) agreement on India as a supplier of generic antiretrovirals. Journal of Pharmaceutical Sciences, 100(3): 816–821. https://doi.org/10.1002/jps.22326.
3. Baker, B. 2020. Gilead remdesivir licenses: Half measures are not nearly good enough. Health GAP (Global Access Project). https://healthgap.org/gilead-remdesivir-licenses-half-measures-are-not-nearly-good-enough/.
4. Beall, R. F., & Kuhn, R. 2012. Trends in compulsory licensing of pharmaceuticals since the doha declaration: A database analysis. PLoS Medicine, 9(1): e1001154. https://doi.org/10.1371/journal.pmed.1001154.
5. Beall, R. F., Kuhn, R., & Attaran, A. 2015. Compulsory licensing often did not produce lower prices for antiretrovirals compared to international procurement. Health Affairs, 34(3): 493–501.
Cited by
31 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献